Abstract
Abstract Among the SARS-CoV-2 vaccines developed to date, the mRNA vaccines developed by the Pfizer/BioNTech and Moderna companies have been formulated using saturated lipids, specifically 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), along with cholesterol. DSPC and cholesterol have the disadvantage of causing sclerosis. Therefore, in this study, lipid nanoparticles (LNPs) were prepared and characterized by replacing DSPC with 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and excluding cholesterol. The results showed that the DOPC-based LNPs had a smaller diameter (75.67 nm) compared to the previous study and the polydispersity index (PI) indicated a good dispersion homogeneity, suggesting size uniformity. Additionally, the LNPs maintained their size between 57 nm and 152 nm and showed stable PI values (0.330–0.393) throughout the 25 days.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
